Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM4JMB)

• Drug Name: CTI-1601 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Friedreich's ataxia	8A03.10	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMM4JMB

Molecule-Related Drug Atlas

Drug(s) Targeting Soluble guanylate cyclase (GCS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[3]
Nitroglycerin	DMQ2491	Angina pectoris	BA40	Approved	[4]
Sodium nitroprusside	DMGA9X0	Hypertension	BA00-BA04	Approved	[5]
IW-1973	DMK2T7J	Heart failure	BD10-BD13	Phase 2	[6]
Runcaciguat	DMCFTTN	Chronic kidney disease	GB61	Phase 2	[7]
MK-5475	DMIIZ4R	Pulmonary arterial hypertension	BB01.0	Phase 2	[8]
CY6463	DM84AVQ	Alzheimer disease	8A20	Phase 2	[9]
CY6463	DM84AVQ	Alzheimer disease	8A20	Phase 2	[10]
(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	DM15P2G	Discovery agent	N.A.	Investigative	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Soluble guanylate cyclase (GCS)	TT23PYC	GCYA1_HUMAN; GCYB1_HUMAN	Stimulator	[2]

References

• [1] ClinicalTrials.gov (NCT05579691) A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Exploration Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 in Adult Subjects With Friedreich's Ataxia. U.S.National Institutes of Health.
• [2] The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases. Front Pharmacol. 2021 May 24;12:656561.
• [3] Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Am J Cardiol. 1996 May 30;77(13):2C-7C.
• [4] Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14.
• [5] Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Crit Care Res Pract.2012;2012:290805.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2021 Dec;394(12):2363-2379.
• [8] Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH). Respir Med. 2023 Jan;206:107065.
• [9] First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator. Clin Transl Sci. 2023 Aug;16(8):1381-1395.
• [10] Clinical pipeline report, company report or official report of Cyclerion Therapeutics